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Abstract: Intraoperative intact parathyroid hormone (iPTH) monitoring has been accepted by 
many centers specializing in parathyroid surgery as a useful adjunct during surgery for primary 
hyperparathyroidism. This method can be utilized in three discreet modes of application: (I) to guide 
surgical decisions during parathyroidectomy in one of the following clinical contexts: (i) to confirm complete 
removal of all hyperfunctioning parathyroid tissue, which allows for termination of surgery with confidence 
that the hyperparathyroid state has been successfully corrected; (ii) to identify patients with additional 
hyperfunctioning parathyroid tissue following the incomplete removal of diseased parathyroid/s, which 
necessitates extended neck exploration in order to minimize the risk of operative failure; (II) to differentiate 
parathyroid from non-parathyroid tissue by iPTH measurement in the fine-needle aspiration washout; (III) 
to lateralize the side of the neck harboring hyperfunctioning parathyroid tissue by determination of jugular 
venous gradient in patients with negative or discordant preoperative imaging studies, in order to increase 
the number of patients eligible for unilateral neck exploration. There are many advantages of minimally 
invasive parathyroidectomy guided by intraoperative iPTH monitoring, including focused dissection in 
order to remove the image-indexed parathyroid adenoma with a similar or even higher operative success 
rate, lower prevalence of complications and shorter operative time when compared to conventional bilateral 
neck exploration. However, to achieve such excellent results, the surgeon needs to be aware of hormone 
dynamics during parathyroidectomy and carefully choose the protocol and interpretation criteria that best fit 
the individual practice. Understanding the nuances of intraoperative iPTH monitoring allows the surgeon 
for achieving intraoperative confidence in predicting operative success and preventing failure in cases of 
unsuspected multiglandular disease, while safely limiting neck exploration in the majority of patients with 
sporadic primary hyperparathyroidism. Thus, parathyroidectomy guided by intraoperative iPTH monitoring 
for the management of sporadic primary hyperparathyroidism is an ideal option for the treatment of this 
disease entity. However, the cost-benefit aspects of the standard application of this method still remain a 
matter of controversy.
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Introduction
Since the time when the first parathyroidectomy was 
performed by Dr. Felix Mandl in 1925, the procedure of 
bilateral neck exploration done by an experienced parathyroid 
surgeon has been for many years the gold standard in 
parathyroid surgery, allowing for achieving cure rates 
exceeding 95% of patients with primary hyperparathyroidism 
(1,2). Nevertheless, the recently developed modern imaging 
techniques allowing for preoperative localization of diseased 
parathyroid gland, such as parathyroid scintigraphy or high-
resolution ultrasonography, followed by developing a method 
of intraoperative quality control of surgical treatment 
based on intraoperative serum intact parathyroid hormone 
(iPTH) assay, became the milestones in forming the idea of 
minimally invasive parathyroidectomy, focusing on using a 
small incision to resect a solitary image-indexed parathyroid 
adenoma without a necessity of intraoperative identification 
and evaluation of the remaining parathyroids (3).
According to the literature published to date, minimally 
invasive parathyroidectomy has proven to be equally effective 
in restoring normocalcemia as bilateral neck exploration 
and is associated with a minimal risk of complications 
(4-6). A fundamental advantage of minimally invasive 
parathyroidectomy, in addition to better cosmetics effects 
and lesser pain is a significant decrease of the percentage of 
postoperative transient hypoparathyroidism to approximately 
5% as compared to approximately 15-25% after bilateral 
neck exploration, as well as complete elimination of the 
risk of permanent hypoparathyroidism. This phenomenon 
is a consequence of preserving intact the blood supply of 
normal parathyroids, which have not been exposed in the 
course of minimally invasive parathyroidectomy. In turn, a 
lower rate of transient hypocalcemia after minimally invasive 
parathyroidectomy is associated with significantly decreased 
requirements for calcium and vitamin D3 preparations and a 
shorter hospitalization (7).
Historical perspective
In  1988,  Nussbaum e t  a l .  modi f ied  the  or ig ina l 
immunoradiometric assay by increasing the temperature 
of incubation and employing a kinetic enhancer; the above 
changes decreased the turnover time to approximately 
15 minutes (8). In this initial report, the first use of iPTH 
monitoring during parathyroidectomy was described, 
although the patients in this series underwent bilateral 
neck exploration and iPTH was measured postoperatively. 
Although the reporting of this experience appeared to 
be of clinical interest, it was not readily accepted as an 
alternative to the existing practice of highly successful 
conventional bilateral neck exploration. In 1990, Chapuis 
et al. from Paris reported in French their series of 13 patients 
in whom the iPTH dropped above 70% in 20 minutes 
after parathyroidectomy by using the immunoradiometric 
assay for intraoperative iPTH measurement (9). Utilizing 
a modification of the technique described by Nussbaum, 
Irvin was able to demonstrate a rapid decline in parathyroid 
hormone levels measured intraoperatively following removal 
of the second parathyroid adenoma. In 1991, Irvin et al. 
described for the first time a series of 21 patients who had 
their parathyroidectomy guided exclusively by intraoperative 
iPTH assay using an immunoradiometric method (10). With 
George Irvin’s help, in 1996, this rapid assay method was 
developed further to an immunochemiluminescence method, 
and the “quick” iPTH assay became commercially available 
for intraoperative use, which is still the methodology 
used today (11). Currently, the majority of high-volume 
parathyroid surgeons utilize this technique to guide 
parathyroidectomy in patients with a sporadic primary 
hyperparathyroidism (12-18). 
Areas of application of intraoperative iPTH 
monitoring
The intraoperative iPTH assay can be utilized in three 
discreet modes of application:
(I) To guide surgical decisions during parathyroidectomy 
in one of the following clinical contexts:
(i) To confirm complete removal of all hyperfunctioning 
parathyroid tissue, which allows for termination of 
surgery with confidence that the hyperparathyroid 
state has been successfully corrected (12-16);
(ii) To identify patients with additional hyperfunctioning 
parathyroid tissue following the incomplete removal 
of diseased parathyroid/s, which necessitates 
extended neck exploration in order to minimize the 
risk of operative failure (17,18);
(II) To differentiate parathyroid from non-parathyroid 
tissue by iPTH measurement in the fine-needle 
aspiration washout (19-21); 
(III) To lateralize the side of the neck harboring 
hyperfunctioning parathyroid tissue by determination 
of jugular venous gradient in patients with negative or 
discordant preoperative imaging studies, in order to 
increase the number of patients eligible for unilateral 
neck exploration (22,23).
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Protocol of intraoperative iPTH assay
A peripheral vein access is most commonly used for 
collection of blood samples. This access should be kept 
open with saline infusion throughout the procedure, and an 
intravenous extension is used to give the anesthesiologist 
access to the tubing for blood collection at times requested 
by the surgeon. It is extremely important to instruct the 
anesthesia team about discarding 10 mL of blood with 
saline to avoid sample dilution, potentially leading to 
falsely lower iPTH values. Totally 3 mL of blood are 
collected for iPTH measurement and are placed in an 
ethylenediaminetetraacetic acid (EDTA) coated tube 
at specific time-points and immediately centrifuged. 
To achieve reliable results, it is strongly recommended 
to follow the strict protocol of blood testing at specific 
time-points during parathyroidectomy, which allows for 
understanding the hormone dynamics during the operation. 
The following time-points of blood sampling for iPTH 
are most commonly used: (I) in the operating room before 
the skin incision is made (pre-incision baseline); (II) just 
before the blood supply to the suspicious parathyroid 
gland is ligated (pre-excision baseline); (III) at 10 minutes 
(10 minutes post-excision); and (IV) occasionally at 
20 minutes after excision (20 minutes post-excision) of the 
suspected abnormal gland (Figure 1). An intraoperative 
iPTH drop of more than 50% from the highest either 
pre-incision or pre-excision baseline at 10 minutes post-
excision is highly accurate in predicting postoperative 
normal or low serum calcium values (Miami criterion). 
The iPTH assay total turnaround time may vary from 8 
to 15 minutes depending on the laboratory. During this 
waiting time, the surgeon can close the incision, but any 
manipulation of the remaining parathyroids should be 
avoided in order to minimize the chance of falsely elevating 
iPTH levels resulting in a delay in hormone drop. If the 
assumed criterion is not met at 10 minutes post-excision, 
the extended neck exploration is undertaken and the 
protocol for blood sampling is repeated for each additional 
excised suspicious parathyroid gland until all hypersecreting 
parathyroid tissue is removed, which is confirmed by 
meeting the criterion. In cases approaching but not meeting 
the assumed criterion of an iPTH drop at 10 minutes post-
excision, some surgeons recommend obtaining an additional 
20-minute post-excision sample for iPTH measurement 
in order to rule out the false negative result of the testing. 
However, such an approach is not uniformly agreed upon 
and some data suggest that extended neck exploration 
Figure 1 The recommended protocol of intraoperative iPTH assay sampling. iPTH, intact parathyroid hormone. 
• Collected in the operating room before skin incision
1) Pre-incision baseline
• Collected after dissection of parathyroid but just before ligation of its 
vessels
2) Pre-excision baseline
• Collected at 10 minutes after removal of the suspicious parathyroid gland
• This is the most accurate sample to predict complete excision of 
hyperfunctioning parathyroid tissue
• If the assumed criterion is met (e.g., > 50% from baseline) the surgery can 
be terminated with confidence that it was successful
3) 10-minute post-excision
• Collected at 20 minutes after removal of the suspicious parathyroid gland
• This sample can be measured in case with inadequate but marked drop of 
iPTH at 10 minutes postexcision (e.g., > 40% but < 50% from baseline)
• If the assumed criterion is not met the extended neck exploration should be 
performed
4) 20-minute post-excision 
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should be rather attempted instead.
Intraoperative iPTH assay criteria for 
prognostication of success
The issue of appropriate patient selection plays a fundamental 
role in achieving a high success rate of minimally invasive 
parathyroidectomy approaching 100%. To achieve a high 
success rate of parathyroidectomy, the surgeon needs to 
be aware of intraoperative hormone dynamics during the 
case and carefully choose the protocol and interpretation 
criteria that best fit the individual practice. Understanding 
the nuances of intraoperative iPTH monitoring allows 
the surgeon for achieving intraoperative confidence in 
predicting operative success and preventing failure in cases of 
unsuspected multiglandular disease, while safely limiting neck 
exploration in the majority of patients with sporadic primary 
hyperparathyroidism. When concordant results of functional 
imaging (e.g., sestamibi scanning) and ultrasound performed 
by an experienced investigator are obtained, minimally 
invasive parathyroidectomy can be safely recommended 
(6,24-26). The prevalence of multiglandular parathyroid 
disease among patients with primary hyperparathyroidism 
and concordant imaging tests varies from 1% to 3.5% 
(26,27). Thus, when preoperative localization with sestamibi 
and ultrasound is concordant for single-gland disease, the 
use of intraoperative iPTH monitoring is of little value. 
However, if preoperative localization with sestamibi and 
ultrasound is not concordant and the surgeon wishes to 
perform a minimally invasive “selective” operation, the use 
of intraoperative iPTH monitoring is recommended, as 
the prevalence of multiglandular disease in this subgroup 
of patients with primary hyperparathyroidism approaches 
17% (25,27,28). Similarly, the use of intraoperative iPTH 
monitoring is recommended for patients undergoing selective 
parathyroidectomy on the basis of a single preoperative 
localization study (27,28).
On the other hand, the accuracy of intraoperative iPTH 
monitoring in the detection of patients with multiglandular 
disease is highly dependent on the criteria applied. Few 
studies have shown that the Miami criterion followed by the 
Vienna criterion is the best balanced among other criteria, 
with the highest accuracy in intraoperative prediction of 
cure (26,29,30). However, the Rome criterion followed by 
the Halle criterion is most useful in intraoperative detection 
of multiglandular disease (26,30,31). Nevertheless, their 
application in patients qualified for minimally invasive 
parathyroidectomy with concordant results of sestamibi 
scanning and ultrasound of the neck would result in a 
significantly higher number of negative conversions 
to bilateral neck explorations and only a marginal 
improvement in the success rate of primary operations (26). 
Thus, the accuracy of intraoperative iPTH monitoring 
is highly dependent on the criteria used by the surgeon 
to predict the outcome of parathyroid surgery. The most 
common criteria used for prognostication of the outcome 
of parathyroid surgery and their predictive values are 
summarized in Table 1 (26). 
Table 1 The most common intraoperative iPTH assay criteria used for prognostication of outcome of parathyroid surgery and their 
predictive values
Criterion Definition for prediction of cure
PPV 
(%)
NPV 
(%)
Overall 
accuracy (%)
Halle An iPTH decay into the low normal range (≤35 ng/L) within 15 minutes after removal of 
the hyperfunctioning parathyroid tissue (H. Dralle, personal communication, 2006)
100.0 14.2 65.0
Miami (29) An iPTH drop of 50% or more from the highest of either preoperative baseline or  
pre-excision level at 10 minutes after excision of hyperfunctioning parathyroid gland(s)
99.6 70.0 97.3
Rome (31) An iPTH decay greater than 50% from the highest pre-excision level, and/or iPTH 
concentration within the reference range at 20 minutes post-excision, and/or ≤7.5 ng/L 
lower than the value at 10 minutes post-excision
100.0 26.3 83.8
Vienna (30) A decay of 50% or greater from the baseline (pre-incision) value within 10 minutes 
following resection
99.6 60.9 92.3
Validated among 260 patients with sporadic primary hyperparathyroidism and concordant results of both sestamibi scanning 
and ultrasound of the neck strongly suggestive for a solitary parathyroid adenoma, with multiglandular parathyroid disease 
encountered in nine patients (26). PPV, positive predictive value; NPV, negative predictive value; iPTH, intact parathyroid hormone. 
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Value of intraoperative iPTH monitoring in 
predicting recurrence
Schneider et al. reported on long-term results of 1,368 
parathyroid operations for primary hyperparathyroidism 
with intraoperative iPTH monitoring, including 1,006 
minimally invasive parathyroidectomies and 380 conventional 
parathyroidectomies. There were no differences in recurrence 
between the minimally invasive and conventionally operated 
groups (2.5% vs. 2.1%; P=0.68), and the operative approach 
did not independently predict recurrent disease in the 
multivariate analysis. However, the percentage decrease in 
intraoperative iPTH was protective against recurrence for 
both the entire cohort (hazard ratio =0.96; 95% confidence 
interval, 0.93-0.99; P=0.03) and the minimally invasive 
subset. In addition, a higher postoperative iPTH levels 
also independently predicted disease recurrence. Thus, the 
percentage decrease in intraoperative iPTH is one of many 
adjuncts the surgeon can use to determine which patients are 
best served by bilateral exploration, whereas the postoperative 
iPTH can guide follow-up after parathyroidectomy (32).
Wachtel et al. analyzed 2,185 subjects undergoing 
parathyroidectomy with intraoperative iPTH monitoring 
and noted that 5.0% (n=110) experienced intraoperative 
failure (defined as failure to decrease iPTH intraoperatively 
by ≥50% and into the normal range). The intraoperative 
failure group had more multiglandular disease (35.2% vs. 
16.6%, P<0.001) and smaller glands (13 vs. 15 mm, P=0.048) 
compared to the patients who experienced intraoperative 
success. On multivariate analysis, post-excision iPTH level 
was statistically, but not clinically, significantly associated 
with intraoperative failure (odds ratio =1.0; 95% confidence 
interval, 1.000-1.003). Persistent hyperparathyroidism was 
identified in 2.5% (n=15) of 592 patients with ≥6-month 
follow-up. Median intraoperative iPTH decrease was lower 
in patients with persistent hyperparathyroidism (67.1% 
vs. 85.8%, P<0.001). Thus, the authors concluded that 
intraoperative failure was associated with higher rates of 
multiglandular disease and smaller parathyroid glands. In 
addition, patients with persistent disease had significantly 
lower decreases in intraoperative iPTH values, but one-half 
of patients who experienced failure by intraoperative iPTH 
assay criterion were eucalcemic 6-month postoperatively (33). 
This observation was also confirmed by Wharry et al., who 
analyzed 1,108 initial parathyroid operations for sporadic 
primary hyperparathyroidism using intraoperative iPTH 
monitoring and reported that a final intraoperative iPTH 
level that was within the normal range and dropped by >50% 
from baseline was a strong predictor of operative success. 
Long-term recurrence was more likely in patients with a final 
intraoperative iPTH level of 41-65 pg/mL than with a level 
≤40 pg/mL (1.2% vs. 0%; P=0.016). Hence, patients with a 
final intraoperative iPTH level between 41-65 pg/mL should 
be followed up beyond 6 months for long-term recurrence (34).
Cost-effectiveness of intraoperative iPTH 
monitoring
The added value of intraoperative iPTH monitoring 
remains controversial, because its ability to prevent failure 
of parathyroidectomy due to unrecognized multiple gland 
disease must be balanced against assay-related costs. Morris 
et al. performed a literature review focused on this issue 
and identified 17 studies involving 4,280 unique patients, 
permitting estimation of base case costs and probabilities 
using a decision tree and cost analysis model (35). The 
base case assumption was that in well-localized primary 
hyperparathyroidism, intraoperative iPTH monitoring 
would increase the success rate of minimally invasive 
parathyroidectomy from 96.3% to 98.8%. The cost of 
intraoperative iPTH varied with operating room time used. 
Intraoperative iPTH monitoring reduced overall treatment 
costs only when total assay-related costs fell below $110 
per case. Inaccurate localization and high reoperation cost 
both independently increased the value of intraoperative 
iPTH monitoring. The intraoperative iPTH strategy was 
cost-saving when the rate of unrecognized multiglandular 
disease exceeded 6% or if the cost of reoperation exceeded 
$12,000 (compared with initial minimally invasive 
parathyroidectomy cost of $3,733). Setting the positive 
predictive value (PPV) of intraoperative iPTH monitoring 
at 100% and reducing the false-negative rate to 0% did not 
substantially alter these findings. The authors concluded 
that institution-specific factors influenced the value of 
intraoperative iPTH monitoring. In the analyzed model, 
intraoperative iPTH monitoring increased the cure rate 
marginally, while incurring approximately 4% of additional 
cost (35). One should also take into consideration that 
advantages and disadvantages of the variety of existing 
intraoperative iPTH monitoring success criteria are 
confusing and their assessment is often contradictory. 
Hence, particularly with respect to cost-benefit aspects, the 
standard application of this method of intraoperative quality 
control even in conventional open parathyroidectomy 
remains a matter of controversy (36). However, the use of 
intraoperative iPTH monitoring compensates for its cost by 
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shortening operative time and obviating the need for frozen 
sections. To decrease the cost of this intraoperative adjunct, 
some hospitals place the assay cart at the central laboratory, 
where the system can be used for other purposes and the 
technician does not need to be relocated to the operative 
room. This surgical adjunct is most helpful in reducing 
operative times when used as a point-of-care system in 
close proximity to the operating room, where PTH levels 
can be reported as soon as possible, allowing for real-time 
operative decisions based on iPTH dynamics (37).
The European Society of Endocrine Surgeons (ESES) 
recommended the use of intraoperative iPTH monitoring 
for patients undergoing “targeted” parathyroidectomy 
on the basis of a single preoperative localization study. If 
preoperative localization with sestamibi and ultrasound 
is not concordant and the surgeon wishes to perform 
a minimally invasive “targeted procedure”, the use of 
intraoperative iPTH monitoring is recommended. When 
preoperative localization with sestamibi and ultrasound is 
concordant for single-gland disease, the use of this adjunct 
is of little value. In addition, the use of intraoperative iPTH 
can be recommended in reoperative parathyroidectomy 
to lateralize hyperfunctioning parathyroid tissue (internal 
jugular vein/s sampling) when preoperative localization 
is uncertain, or to predict cure and reduce the need for 
continued exploration in the scarred neck (28).
Other applications for intraoperative iPTH 
monitoring
Intraoperative iPTH assay can be utilized to differentiate 
between parathyroid and non-parathyroid tissue, such as 
thyroid nodules and lymph nodes, with a specificity of 
100% by iPTH measurement in the fine-needle aspiration 
washout (19-21). The aspirated content in the needle is 
diluted with 1 mL of saline solution, centrifuged, and the 
supernatant is used for iPTH measurement. This technique 
is faster than frozen section if the quick assay is used as a 
point-of-care system, which can be very helpful when gland 
identification is difficult, e.g., in the case of an intrathyroidal 
parathyroid or a lesion that could be a thyroid nodule versus 
a subcapsular parathyroid gland (37).
In addition, intraoperative iPTH measurement can 
be used to lateralize the side of the neck harboring 
hyperfunctioning parathyroid tissue by determination 
of jugular venous gradient in patients with negative or 
discordant preoperative imaging studies, in order to 
increase the number of patients eligible for unilateral neck 
exploration (22,23). In this technique, which is positive 
in 70% to 81% of cases, 3 mL of whole blood is collected 
under ultrasound guidance from the most caudal portion 
in the neck of both internal jugular veins, just before skin 
incision. Intact PTH levels are then measured in both 
jugular vein samples, as well as in the initially collected 
sample from the peripheral access (37). The unilateral 
neck exploration is undertaken on the side of the neck 
indexed by the highest iPTH value and terminated after 
successful removal of a hyperfunctioning parathyroid gland 
using intraoperative iPTH monitoring to assure cure from 
hyperparathyroid state.
Conclusions
Minimally invasive parathyroidectomy guided by 
intraoperative PTH monitoring is widely accepted among 
parathyroid surgeons for the treatment of sporadic primary 
hyperparathyroidism. This intraoperative adjunct warrants 
the operation to be a safe, highly successful, less invasive 
procedure, and is associated with a lower prevalence 
of morbidity than bilateral neck exploration. Surgical 
awareness of hormone dynamics during parathyroidectomy 
and adherence to the sampling protocol and interpretation 
criteria that best fit the individual practice are crucial 
in achieving intraoperative confidence in predicting 
operative success and preventing failure in cases of 
unsuspected multiglandular disease, while safely limiting 
neck exploration in the majority of patients with sporadic 
primary hyperparathyroidism.
Acknowledgements
Disclosure: The authors declare no conflict of interest.
References
1. Low RA, Katz AD. Parathyroidectomy via bilateral 
cervical exploration: a retrospective review of 866 cases. 
Head Neck 1998;20:583-7.
2. Allendorf J, DiGorgi M, Spanknebel K, et al. 1112 
consecutive bilateral neck explorations for primary 
hyperparathyroidism. World J Surg 2007;31:2075-80. 
3. Chen H, Mack E, Starling JR. A comprehensive evaluation 
of perioperative adjuncts during minimally invasive 
parathyroidectomy: which is most reliable? Ann Surg 
2005;242:375-80; discussion 380-3.
4. Miccoli P, Berti P, Materazzi G, et al. Results of video-
42 Barczyński et al. Intraoperative iPTH assay
© Gland Surgery. All rights reserved. Gland Surgery 2015;4(1):36-43www.glandsurgery.org
assisted parathyroidectomy: single institution's six-year 
experience. World J Surg 2004;28:1216-8. 
5. Udelsman R. Six hundred fifty-six consecutive explorations 
for primary hyperparathyroidism. Ann Surg 2002;235:665-
70; discussion 670-2.
6. Barczyński M, Cichoń S, Konturek A, et al. Minimally 
invasive video-assisted parathyroidectomy versus open 
minimally invasive parathyroidectomy for a solitary 
parathyroid adenoma: a prospective, randomized, blinded 
trial. World J Surg 2006;30:721-31.
7. Bergenfelz A, Kanngiesser V, Zielke A, et al. Conventional 
bilateral cervical exploration versus open minimally 
invasive parathyroidectomy under local anaesthesia for 
primary hyperparathyroidism. Br J Surg 2005;92:190-7.
8. Nussbaum SR, Thompson AR, Hutcheson KA, et al. 
Intraoperative measurement of parathyroid hormone in 
the surgical management of hyperparathyroidism. Surgery 
1988;104:1121-7.
9. Chapuis Y, Fulla Y, Icard P, et al. Peroperative assay 
of active parathormone 1-84 in surgery of primary 
hyperparathyroidism. Presse Med 1990;19:1461-2.
10. Irvin GL 3rd, Dembrow VD, Prudhomme DL. Operative 
monitoring of parathyroid gland hyperfunction. Am J Surg 
1991;162:299-302.
11. Boggs JE, Irvin GL 3rd, Molinari AS, et al. Intraoperative 
parathyroid hormone monitoring as an adjunct to 
parathyroidectomy. Surgery 1996;120:954-8.
12. Irvin GL 3rd, Carneiro DM, Solorzano CC. Progress 
in the operative management of sporadic primary 
hyperparathyroidism over 34 years. Ann Surg 
2004;239:704-8; discussion 708-11.
13. Irvin GL 3rd, Solorzano CC, Carneiro DM. Quick 
intraoperative parathyroid hormone assay: surgical adjunct 
to allow limited parathyroidectomy, improve success rate, 
and predict outcome. World J Surg 2004;28:1287-92. 
14. Grant CS, Thompson G, Farley D, et al. Primary 
hyperparathyroidism surgical management since the 
introduction of minimally invasive parathyroidectomy: 
Mayo Clinic experience. Arch Surg 2005;140:472-8; 
discussion 478-9.
15. Westerdahl J, Bergenfelz A. Sestamibi scan-directed 
parathyroid surgery: potentially high failure rate without 
measurement of intraoperative parathyroid hormone. 
World J Surg 2004;28:1132-8.
16. Chen H, Pruhs Z, Starling JR, et al. Intraoperative 
parathyroid hormone testing improves cure rates in 
patients undergoing minimally invasive parathyroidectomy. 
Surgery 2005;138:583-7; discussion 587-90.
17. Cayo AK, Sippel RS, Schaefer S, et al. Utility of 
intraoperative PTH for primary hyperparathyroidism due 
to multigland disease. Ann Surg Oncol 2009;16:3450-4. 
18. Hughes DT, Miller BS, Doherty GM, et al. Intraoperative 
parathyroid hormone monitoring in patients with 
recognized multiglandular primary hyperparathyroidism. 
World J Surg 2011;35:336-41.
19. Chan RK, Ibrahim SI, Pil P, et al. Validation of a method 
to replace frozen section during parathyroid exploration by 
using the rapid parathyroid hormone assay on parathyroid 
aspirates. Arch Surg 2005;140:371-3.
20. Barczynski M, Golkowski F, Konturek A, et al. 
Technetium-99m-sestamibi subtraction scintigraphy 
vs. ultrasonography combined with a rapid parathyroid 
hormone assay in parathyroid aspirates in preoperative 
localization of parathyroid adenomas and in directing 
surgical approach. Clin Endocrinol (Oxf) 2006;65:106-13.
21. James BC, Nagar S, Tracy M, et al. A novel, ultrarapid 
parathyroid hormone assay to distinguish parathyroid from 
nonparathyroid tissue. Surgery 2014;156:1638-43.
22. Lew JI, Solorzano CC, Montano RE, et al. Role of 
intraoperative parathormone monitoring during 
parathyroidectomy in patients with discordant localization 
studies. Surgery 2008;144:299-306. 
23. Barczynski M, Konturek A, Hubalewska-Dydejczyk A, 
et al. Utility of intraoperative bilateral internal jugular 
venous sampling with rapid parathyroid hormone testing 
in guiding patients with a negative sestamibi scan for 
minimally invasive parathyroidectomy--a randomized 
controlled trial. Langenbecks Arch Surg 2009;394:827-35.
24. Mihai R, Barczynski M, Iacobone M, et al. Surgical 
strategy for sporadic primary hyperparathyroidism an 
evidence-based approach to surgical strategy, patient 
selection, surgical access, and reoperations. Langenbecks 
Arch Surg 2009;394:785-98.  
25. Bergenfelz AO, Hellman P, Harrison B, et al. Positional 
statement of the European Society of Endocrine Surgeons 
(ESES) on modern techniques in pHPT surgery. 
Langenbecks Arch Surg 2009;394:761-4. 
26. Barczynski M, Konturek A, Hubalewska-Dydejczyk A, 
et al. Evaluation of Halle, Miami, Rome, and Vienna 
intraoperative iPTH assay criteria in guiding minimally 
invasive parathyroidectomy. Langenbecks Arch Surg 
2009;394:843-9. 
27. Barczynski M, Konturek A, Cichon S, et al. Intraoperative 
parathyroid hormone assay improves outcomes of 
minimally invasive parathyroidectomy mainly in patients 
with a presumed solitary parathyroid adenoma and missing 
43Gland Surgery, Vol 4, No 1 February 2015
© Gland Surgery. All rights reserved. Gland Surgery 2015;4(1):36-43www.glandsurgery.org
Cite this article as: Barczyński M, Gołkowski F, Nawrot I. 
The current status of intraoperative iPTH assay in surgery for 
primary hyperparathyroidism. Gland Surg 2015:4(1):36-43. doi: 
10.3978/j.issn.2227-684X.2015.01.01
concordance of preoperative imaging. Clin Endocrinol 
(Oxf) 2007;66:878-85.
28. Harrison BJ, Triponez F. Intraoperative adjuncts in surgery 
for primary hyperparathyroidism. Langenbecks Arch Surg 
2009;394:799-809. 
29. Carneiro DM, Solorzano CC, Nader MC, et al. 
Comparison of intraoperative iPTH assay (QPTH) criteria 
in guiding parathyroidectomy: which criterion is the most 
accurate? Surgery 2003;134:973-9; discussion 979-81.
30. Riss P, Kaczirek K, Heinz G, et al. A "defined baseline" in 
PTH monitoring increases surgical success in patients with 
multiple gland disease. Surgery 2007;142:398-404.
31. Lombardi CP, Raffaelli M, Traini E, et al. Intraoperative 
PTH monitoring during parathyroidectomy: the need 
for stricter criteria to detect multiglandular disease. 
Langenbecks Arch Surg 2008;393:639-45. 
32. Schneider DF, Mazeh H, Chen H, et al. Predictors of 
recurrence in primary hyperparathyroidism: an analysis of 
1386 cases. Ann Surg 2014;259:563-8.
33. Wachtel H, Cerullo I, Bartlett EK, et al. What Can We 
Learn from Intraoperative Parathyroid Hormone Levels 
that Do Not Drop Appropriately? Ann Surg Oncol 2014. 
[Epub ahead of print].
34. Wharry LI, Yip L, Armstrong MJ, et al. The final 
intraoperative parathyroid hormone level: how low should 
it go? World J Surg 2014;38:558-63. 
35. Morris LF, Zanocco K, Ituarte PH, et al. The value 
of intraoperative parathyroid hormone monitoring in 
localized primary hyperparathyroidism: a cost analysis. 
Ann Surg Oncol 2010;17:679-85. 
36. Lorenz K, Dralle H. Intraoperative parathyroid hormone 
determination for primary hyperparathyroidism. Chirurg 
2010;81:636, 638-42.
37. Carneiro-Pla D, Pellitteri PK. Intraoperative PTH 
monitoring during parathyroid surgery. In: Randolph GW. 
eds. Surgery of the thyroid and parathyroid glands, 2nd ed. 
Philadelphia: Elsevier Saunders, 2013:605-12.
